全文获取类型
收费全文 | 3973篇 |
免费 | 182篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 85篇 |
妇产科学 | 88篇 |
基础医学 | 480篇 |
口腔科学 | 80篇 |
临床医学 | 275篇 |
内科学 | 1055篇 |
皮肤病学 | 82篇 |
神经病学 | 399篇 |
特种医学 | 142篇 |
外科学 | 670篇 |
综合类 | 22篇 |
预防医学 | 203篇 |
眼科学 | 26篇 |
药学 | 233篇 |
中国医学 | 25篇 |
肿瘤学 | 312篇 |
出版年
2023年 | 29篇 |
2022年 | 34篇 |
2021年 | 104篇 |
2020年 | 69篇 |
2019年 | 91篇 |
2018年 | 136篇 |
2017年 | 76篇 |
2016年 | 97篇 |
2015年 | 125篇 |
2014年 | 168篇 |
2013年 | 247篇 |
2012年 | 303篇 |
2011年 | 324篇 |
2010年 | 202篇 |
2009年 | 160篇 |
2008年 | 303篇 |
2007年 | 267篇 |
2006年 | 246篇 |
2005年 | 262篇 |
2004年 | 225篇 |
2003年 | 197篇 |
2002年 | 190篇 |
2001年 | 28篇 |
2000年 | 23篇 |
1999年 | 15篇 |
1998年 | 31篇 |
1997年 | 18篇 |
1996年 | 20篇 |
1995年 | 21篇 |
1994年 | 19篇 |
1993年 | 17篇 |
1992年 | 13篇 |
1991年 | 14篇 |
1990年 | 9篇 |
1989年 | 11篇 |
1988年 | 14篇 |
1987年 | 13篇 |
1986年 | 7篇 |
1985年 | 7篇 |
1984年 | 6篇 |
1983年 | 4篇 |
1982年 | 8篇 |
1981年 | 4篇 |
1980年 | 8篇 |
1977年 | 3篇 |
1975年 | 3篇 |
1972年 | 2篇 |
1971年 | 2篇 |
1969年 | 2篇 |
1931年 | 2篇 |
排序方式: 共有4194条查询结果,搜索用时 125 毫秒
1.
Del Lama Rafael Silva Candido Raquel Mariana Chiari-Correia Natália Santana Nogueira-Barbosa Marcello Henrique de Azevedo-Marques Paulo Mazzoncini Tinós Renato 《Journal of digital imaging》2022,35(3):446-458
Journal of Digital Imaging - Vertebral Compression Fracture (VCF) occurs when the vertebral body partially collapses under the action of compressive forces. Non-traumatic VCFs can be secondary to... 相似文献
2.
3.
4.
5.
Matteo Lambertini Francesca Poggio Marco Bruzzone Benedetta Conte Claudia Bighin Evandro de Azambuja Mario Giuliano Michele De Laurentiis Francesco Cognetti Alessandra Fabi Giancarlo Bisagni Antonio Durando Anna Turletti Ylenia Urracci Ornella Garrone Fabio Puglisi Filippo Montemurro Marcello Ceppi Lucia Del Mastro the GIM investigators 《International journal of cancer. Journal international du cancer》2020,147(1):160-169
Dose-dense adjuvant chemotherapy is standard of care in high-risk early breast cancer patients. However, its role in HER2-positive patients is still uncertain. In this exploratory analysis of the GIM2 trial, we investigated the efficacy of dose-dense chemotherapy in HER2-positive breast cancer patients with or without exposure to trastuzumab. In the GIM2 trial, node-positive early breast cancer patients were randomized to receive four cycles of (fluorouracil)epirubicin/cyclophosphamide followed by four cycles of paclitaxel administered every 2 (dose-dense) or 3 (standard-interval) weeks. After approval of adjuvant trastuzumab, protocol was amended in April 2006 to allow use of trastuzumab for 1 year after chemotherapy completion in HER2-positive patients. The efficacy of dose-dense chemotherapy in terms of disease-free survival (DFS) and overall survival (OS) was assessed according to HER2 status and trastuzumab use. Out of 2,003 breast cancer patients, HER2 status was negative/unknown in 1,551 patients; among the 452 patients with HER2-positive breast cancer, chemotherapy alone or followed by trastuzumab was given to 320 and 132 patients, respectively. Median follow-up was 8.1 years. No significant interaction between HER2 status, trastuzumab use and chemotherapy treatment was observed for both DFS (p = 0.698) and OS (p = 0.708). Nevertheless, there was no apparent benefit in the HER2-positive group treated with trastuzumab (DFS: HR, 0.99; 95% CI 0.52–1.89; OS: HR, 0.95; 95% CI 0.37–2.41). Although dose-dense chemotherapy was associated with a significant survival improvement in high-risk breast cancer patients, its benefit appeared to be smaller (if any) in patients with HER2-positive disease who received adjuvant trastuzumab. 相似文献
6.
Susanna Zanutto Chiara Maura Ciniselli Antonino Belfiore Mara Lecchi Enzo Masci Gabriele Delconte Massimo Primignani Giulia Tosetti Marco Dal Fante Linda Fazzini Aldo Airoldi Marcello Vangeli Francesca Turpini Giovanni Giuseppe Rubis Passoni Paolo Viaggi Monica Arena Roberta Ilaria Olimpia Motta Anna Maria Cantù Cristiano Crosta Giuseppe De Roberto Francesca Iannuzzi Andrea Cassinotti Valentina Dall'Olio Laura Tizzoni Gabriella Sozzi Emanuele Meroni Luigi Bisanti Marco Alessandro Pierotti Paolo Verderio Manuela Gariboldi 《International journal of cancer. Journal international du cancer》2020,146(4):1164-1173
Colorectal cancer (CRC) screening programs help diagnose cancer precursors and early cancers and help reduce CRC mortality. However, currently recommended tests, the fecal immunochemical test (FIT) and colonoscopy, have low uptake. There is therefore a pressing need for screening strategies that are minimally invasive and consequently more acceptable to patients, most likely blood based, to increase early CRC identification. MicroRNAs (miRNAs) released from cancer cells are detectable in plasma in a remarkably stable form, making them ideal cancer biomarkers. Using plasma samples from FIT-positive (FIT+) subjects in an Italian CRC screening program, we aimed to identify plasma circulating miRNAs that detect early CRC. miRNAs were initially investigated by quantitative real-time PCR in plasma from 60 FIT+ subjects undergoing colonoscopy at Fondazione IRCCS Istituto Nazionale dei Tumori, then tested on an internal validation cohort (IVC, 201 cases) and finally in a large multicenter prospective series (external validation cohort [EVC], 1121 cases). For each endoscopic lesion (low-grade adenoma [LgA], high-grade adenoma [HgA], cancer lesion [CL]), specific signatures were identified in the IVC and confirmed on the EVC. A two-miRNA-based signature for CL and six-miRNA signatures for LgA and HgA were selected. In a multivariate analysis including sex and age at blood collection, the areas under the receiver operating characteristic curve (95% confidence interval) of the signatures were 0.644 (0.607–0.682), 0.670 (0.626–0.714) and 0.682 (0.580–0.785) for LgA, HgA and CL, respectively. A miRNA-based test could be introduced into the FIT+ workflow of CRC screening programs so as to schedule colonoscopies only for subjects likely to benefit most. 相似文献
7.
8.
Kadarkarai Murugan Narayanan Aarthi Kalimuthu Kovendan Chellasamy Panneerselvam Balamurugan Chandramohan Palanisamy Mahesh Kumar Duraisamy Amerasan Manickam Paulpandi Ramachandran Chandirasekar Devakumar Dinesh Udaiyan Suresh Jayapal Subramaniam Akon Higuchi Abdullah A. Alarfaj Marcello Nicoletti Heinz Mehlhorn Giovanni Benelli 《Parasitology research》2015,114(10):3657-3664
9.
10.
Wilma Barcellini Anna Zaninoni Anna I. Gregorini Giulia Soverini Lorena Duca Bruno Fattizzo Juri A. Giannotta Patrizia Pedrotti Cristina Vercellati Anna P. Marcello Elisa Fermo Paola Bianchi Maria Domenica Cappellini 《British journal of haematology》2019,185(3):523-531
Iron overload (IO) is poorly investigated in the congenital haemolytic anaemias (CHAs), a heterogeneous group of rare inherited diseases encompassing abnormalities of the erythrocyte membrane and metabolism, and defects of the erythropoiesis. In this study we systematically evaluated routine iron parameters and cardiac and hepatic magnetic resonance imaging, together with erythropoietin, hepcidin, non-transferrin bound iron (NTBI), and cytokine serum levels in patients with different CHAs. We found that 40% of patients had a liver iron concentration (LIC) >4 mg Fe/g dry weight. Hepatic IO was associated with ferritin levels (P = 0·0025), transferrin saturation (TfSat, P = 0·002) and NTBI (P = 0·003). Moreover, ferritin >500 μg/l plus TfSat >60% was demonstrated as the best combination able to identify increased LIC, and TfSat alteration as more important in cases with discordant values. Possible confounding factors, such as transfusions, hepatic disease, metabolic syndrome and hereditary haemochromatosis-associated mutations, had negligible effects on IO. Erythropoietin and hepcidin levels were increased in CHAs compared with controls, correlating with LIC and ferritin, respectively. Regarding cytokines, γ-interferon (IFN-γ) was increased, and both interleukin 6 and IFN-γ levels positively correlated with ferritin and hepcidin levels. Overall, these findings suggest the existence of a vicious cycle between chronic haemolysis, inflammatory response and IO in CHAs. 相似文献